These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Serum level of fibroblast growth factor 21 predicts long-term prognosis in patients with both diabetes mellitus and coronary artery calcification. Gan F; Huang J; Dai T; Li M; Liu J Ann Palliat Med; 2020 Mar; 9(2):368-374. PubMed ID: 32268770 [TBL] [Abstract][Full Text] [Related]
9. Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial. Bergmark BA; Udell JA; Morrow DA; Cannon CP; Steen DL; Jarolim P; Budaj A; Hamm C; Guo J; Im K; Kuder JF; Braunwald E; Sabatine MS; O'Donoghue ML JAMA Cardiol; 2018 Jun; 3(6):473-480. PubMed ID: 29710336 [TBL] [Abstract][Full Text] [Related]
10. Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate. González-Parra E; Aceña Á; Lorenzo Ó; Tarín N; González-Casaus ML; Cristóbal C; Huelmos A; Mahíllo-Fernández I; Pello AM; Carda R; Hernández-González I; Alonso J; Rodríguez-Artalejo F; López-Bescós L; Ortiz A; Egido J; Tuñón J J Bone Miner Metab; 2016 Sep; 34(5):587-98. PubMed ID: 26298279 [TBL] [Abstract][Full Text] [Related]
11. The fibroblast growth factor-23 and Vitamin D emerge as nontraditional risk factors and may affect cardiovascular risk. Masson S; Agabiti N; Vago T; Miceli M; Mayer F; Letizia T; Wienhues-Thelen U; Mureddu GF; Davoli M; Boccanelli A; Latini R; J Intern Med; 2015 Mar; 277(3):318-330. PubMed ID: 24620922 [TBL] [Abstract][Full Text] [Related]
12. Impact of renal function on the prognostic value of mineral metabolism in patients with chronic ischaemic heart disease patients with chronic ischaemic heart disease. Aceña Á; Pello-Lázaro AM; Martínez-Milla J; González-Lorenzo Ó; Tarín N; Cristóbal C; Blanco-Colio LM; Martín-Ventura JL; Huelmos A; López-Castillo M; Alonso J; Gutiérrez-Landaluce C; López Bescós L; Alonso-Pulpón L; González-Parra E; Egido J; Mahíllo-Fernández I; Lorenzo Ó; González-Casaus ML; Tuñón J Clin Investig Arterioscler; 2022; 34(1):1-9. PubMed ID: 34876305 [TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. Isakova T; Xie H; Yang W; Xie D; Anderson AH; Scialla J; Wahl P; Gutiérrez OM; Steigerwalt S; He J; Schwartz S; Lo J; Ojo A; Sondheimer J; Hsu CY; Lash J; Leonard M; Kusek JW; Feldman HI; Wolf M; JAMA; 2011 Jun; 305(23):2432-9. PubMed ID: 21673295 [TBL] [Abstract][Full Text] [Related]
14. Age-Biomarkers-Clinical Risk Factors for Prediction of Cardiovascular Events in Patients With Coronary Artery Disease. Wong YK; Cheung CYY; Tang CS; Au KW; Hai JSH; Lee CH; Lau KK; Cheung BMY; Sham PC; Xu A; Lam KSL; Tse HF Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2519-2527. PubMed ID: 30354221 [TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. Udell JA; Morrow DA; Jarolim P; Sloan S; Hoffman EB; O'Donnell TF; Vora AN; Omland T; Solomon SD; Pfeffer MA; Braunwald E; Sabatine MS J Am Coll Cardiol; 2014 Jun; 63(22):2421-8. PubMed ID: 24727254 [TBL] [Abstract][Full Text] [Related]
17. Fibroblast Growth Factor 23 and α-Klotho Protein Are Associated with Adverse Clinical Outcomes in Non-Dialysis CKD Patients. Manou E; Thodis E; Arsos G; Pasadakis P; Panagoutsos S; Papadopoulou D; Papagianni A Kidney Blood Press Res; 2020; 45(6):900-915. PubMed ID: 33040068 [TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD. Smith K; deFilippi C; Isakova T; Gutiérrez OM; Laliberte K; Seliger S; Kelley W; Duh SH; Hise M; Christenson R; Wolf M; Januzzi J Am J Kidney Dis; 2013 Jan; 61(1):67-73. PubMed ID: 22883134 [TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Kanbay M; Nicoleta M; Selcoki Y; Ikizek M; Aydin M; Eryonucu B; Duranay M; Akcay A; Armutcu F; Covic A Clin J Am Soc Nephrol; 2010 Oct; 5(10):1780-6. PubMed ID: 20576822 [TBL] [Abstract][Full Text] [Related]
20. Association of Fibroblast Growth Factor-23 Levels and Angiotensin-Converting Enzyme Inhibition in Chronic Systolic Heart Failure. Wohlfahrt P; Melenovsky V; Kotrc M; Benes J; Jabor A; Franekova J; Lemaire S; Kautzner J; Jarolim P JACC Heart Fail; 2015 Oct; 3(10):829-39. PubMed ID: 26450001 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]